- PAH Pathways(TM) Program offers Patient Support and Financial Assistance
SOUTH SAN FRANCISCO, Calif., Dec. 18 /PRNewswire/ -- Actelion
Pharmaceuticals US, Inc. today announced results of a recent Harris
Interactive(R) survey, showing that an overwhelming majority of Tracleer
patients enrolled in Sure Steps find the patient support program valuable,
and feel that their knowledge of pulmonary arterial hypertension (PAH) and
Tracleer have improved due to the program. The Sure Steps program, part of
Actelion's PAH Pathways(TM) service and support program, is a support and
education program available to all PAH patients on Actelion's PAH products,
Tracleer and Ventavis(R) (iloprost) Inhalation Solution.
Key findings from the survey of patients enrolled in Sure Steps show that:
-- Nine in ten (89 percent) enrolled patients are satisfied with the
-- Almost all (97 percent) would recommend the program to other PAH
patients on Tracleer;
-- Six out of seven (85 percent) enrolled patients are more comfortable
discussing their PAH therapy with their physicians because of the
-- 92 percent feel better informed about Tracleer as a result of
information provided in the program.
The survey was conducted by Harris Interactive on behalf of Actelion between August 7 and August 21, 2007. It included more than 600 patients currently enrolled in Sure Steps, 256 of whom who had been on Tracleer for less than one year, and 354 patients who had been on Tracleer for more than a year. All patients were 18 year of age or older, diagnosed with PAH, currently taking Tracleer, and had been enrolled in the Sure Steps program for at least two months.
"When patients are first diagnosed with PAH and begin treatment, they
are often overwhelmed by their diagnosis and have many questions about
treatment," said Craig Hopkinson, MD, Vice
|SOURCE Actelion Pharmaceuticals US, Inc.|
Copyright©2007 PR Newswire.
All rights reserved